Search results for "Carbapenem resistant"

showing 4 items of 4 documents

Erratum for Yahav et al., "New β-Lactam-β-Lactamase Inhibitor Combinations".

2021

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa. Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, a…

0301 basic medicineMicrobiology (medical)General Immunology and MicrobiologyCarbapenem resistantbiologyEpidemiologyChemistryStereochemistryKlebsiella pneumoniae030106 microbiologyPublic Health Environmental and Occupational HealthReviewbiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycoses03 medical and health scienceschemistry.chemical_compound030104 developmental biologyInfectious Diseasesβ lactamase inhibitorLactampolycyclic compoundsbacteriaClinical microbiology reviews
researchProduct

Co-colonization with carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii in intensive care unit patients

2013

Objectives: This investigation was conducted to study co-colonization by carbapenem-resistant Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) and Acinetobacter baumannii (CRAB) in intensive care unit (ICU) patients in Palermo, Sicily, a geographic area where both organisms are endemic in the healthcare setting. Risk factors at admission and during ICU stay and outcomes were also evaluated. Methods: All patients colonized by KPC-Kp, or CRAB, or both in 2 ICUs of a large general hospital during the period October 2011 – March 2012 were enrolled. Demographics and clinical data were collected. Resistance determinants and clonality of the 2 organisms were characterized by mo…

Acinetobacter baumanniiAdultMaleMicrobiology (medical)medicine.medical_specialtyPediatricsYounger ageGenotypeCarbapenem resistant Klebsiella pneumoniaeKlebsiella pneumoniaeCritical IllnessSettore MED/42 - Igiene Generale E ApplicataHospitals Generalbeta-Lactamaseslaw.inventionBacterial ProteinsRisk FactorslawInternal medicineDrug Resistance BacterialmedicineHumansGeneral hospitalSicilyAgedAged 80 and overGeneral Immunology and MicrobiologybiologyCoinfectionbusiness.industryMajor traumaGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseIntensive care unitCarbapenem resistance co-colonization intensive care unit risk factorsKlebsiella InfectionsAcinetobacter baumanniiMolecular TypingIntensive Care UnitsKlebsiella pneumoniaeInfectious DiseasesFemaleCo colonizationbusinessAcinetobacter InfectionsScandinavian Journal of Infectious Diseases
researchProduct

Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, Italy

2012

Abstract Background Multidrug-resistant Acinetobacter baumannii, initially considered as having a poor clinical relevance, is frequently isolated from infection cases in intensive care units. We describe the epidemiology of carbapenem resistant A. baumannii (CRAB) in a general ICU in Palermo, Italy, from October 2010 to March 2011. Findings 58 of 61 isolates exhibited MICs for meropenem or imipenem ≥16 mg/L. Forty-nine carried blaOXA-23 and two blaOXA-58 genes. Five subtype clusters were detected by rep-PCR. Clusters D and E included 10 isolates that tested negative for the carbapenem resistance genes. MLST attributed all isolates, but two, with sequence type (ST)2, whereas the two remainin…

MaleAcinetobacter baumanniiImipenemSettore MED/07 - Microbiologia E Microbiologia ClinicaTime Factorslcsh:MedicineTigecyclinePolymerase Chain Reactionintensive care unitlaw.inventionlawDrug Resistance Multiple BacterialEpidemiologypolycyclic compoundsMedicinelcsh:QH301-705.5Medicine(all)Aged 80 and overbiologyGeneral MedicineMiddle AgedIntensive care unitAcinetobacter baumanniiIntensive Care UnitsItalyFemaleAcinetobacter baumannii; intensive care unitAcinetobacter Infectionsmedicine.drugAdultmedicine.medical_specialtyAdolescentShort ReportMicrobial Sensitivity TestsMeropenemGeneral Biochemistry Genetics and Molecular BiologyYoung AdultIntensive careHumansIntensive care medicinelcsh:Science (General)AgedDemographyBiochemistry Genetics and Molecular Biology(all)business.industrylcsh:Rbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationClone CellsCarbapenemslcsh:Biology (General)bacteriabusinessCarbapenem resistant Acinetobacter baumanniilcsh:Q1-390BMC Research Notes
researchProduct

Multiclonal emergence of carbapenem-resistant Klebsiella pneumoniae in Tuscany, Italy

2010

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaImipenemGenotypemedicine.drug_classCarbapenem resistant Klebsiella pneumoniaemedicine.medical_treatmentAntibioticsMicrobial Sensitivity TestsBiologySettore MED/42 - Igiene Generale E ApplicataMeropenembeta-Lactam Resistancebeta-LactamasesMicrobiologychemistry.chemical_compoundmedicineHumansPharmacology (medical)Molecular EpidemiologyKlebsiella pneumoniae resistenza ai carbapenemi multiclonaleGeneral MedicineDNA FingerprintingAnti-Bacterial AgentsBacterial Typing TechniquesElectrophoresis Gel Pulsed-FieldKlebsiella InfectionsMultiple drug resistanceKlebsiella pneumoniaePhenotypeInfectious DiseasesCarbapenemsItalychemistryBeta-lactamaseErtapenemmedicine.drugBeta lactam antibioticsInternational Journal of Antimicrobial Agents
researchProduct